Advances in the value of eggs and egg components for human health

Journal of Agricultural and Food Chemistry

Volumn 53, Issue 22, 2005, Pages 8421-8431

  Kovacs Nolan, Jennifer ^a   Phillips, Marshall ^b   Mine, Yoshinori ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b Strategic Bioconnections   (United States)

Author keywords

Avian eggs; Bioactive proteins and peptides; Chronic diseases; Egg white; Functional foods; Human health; Nutraceuticals; Yolk

Indexed keywords

ANTIINFECTIVE AGENT; ANTIOXIDANT; EGG PROTEIN; EGG WHITE;

ANIMAL; EGG; EGG YOLK; HEALTH PROMOTION; HUMAN; HYPERTENSION; IMMUNITY; NEOPLASM; NUTRITION; REVIEW;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIOXIDANTS; EGG PROTEINS; EGG WHITE; EGG YOLK; EGGS; HEALTH PROMOTION; HUMANS; HYPERTENSION; IMMUNITY; NEOPLASMS; NUTRITION PHYSIOLOGY;

ANIMALIA; AVES; BACTERIA (MICROORGANISMS);

EID: 27744563959     PISSN: 00218561     EISSN: None     Source Type: Journal    
DOI: 10.1021/jf050964f     Document Type: Review

References (181)

1. Cotterill, O. J.; Geiger, G. S. Egg product yield trends from shell eggs. Poult. Sci. 1977, 56, 1027-1031.
2. Burley, R. W.; Vadehra, D. V. The Avian Egg, Chemistry and Biology; Wiley: New York, 1989.
3. Li-Chan, E. C. Y.; Powrie, W. D.; Nakai, S. The chemistry of eggs and egg products. In Egg Science and Technology, 4th ed.; Stadelman, W. J., Cotterill, O. J., Eds.; Haworth Press: New York, 1995; pp 105-175.
4. Sugino, H.; Nitoda, T.; Juneja, L. R. General chemical composition of hen eggs. In Hen Eggs, Their Basic and Applied Science; Yamamoto, T., Juneja, L. R., Hatta, H., Kim, M., Eds.; CRC Press: New York, 1997; pp 13-24.
5. Mine, Y. Recent advances in egg protein functionality in the food system. World's Poult. Sci. J. 2002, 58, 31-39.
6. Brady, D.; Lowe, N.; Gaines, S.; Fenelon, L.; McPartlin, J.; O'Farrelly, C. Inhibition of Streptococcus mutans growth by hen egg-derived fatty acids. J. Food Sci. 2003, 68, 1433-1437.
7. Li-Chan, E.; Nakai, S. Biochemical basis for the properties of egg white. Crit. Rev. Poult. Biol. 1989, 2, 21-58.
8. Salton, M. J. R. The properties of lysozyme and its action on microorganisms. Bacteriol. Rev. 1957, 21, 82-98.
9. Hughey, V. L.; Johnson, E. A. Antimicrobial activity of lysozyme against bacteria involved in food spoilage and food-borne disease. Appl. Environ. Microbiol. 1987, 53, 2165-2170.
10. Losso, J. N.; Nakai, S.; Charter, E. A. Lysozyme. In Natural Food Antimicrobial Systems; Naidu, A. S., Ed.; CRC Press: New York, 2000; pp 185-210.
11. Ibrahim, H. R.; Aoki, T.; Pellegrini, A. Strategies for new antimicrobial proteins and peptides: lysozyme and aprotinin as model molecules. Curr. Pharm. Des. 2002, 8, 671-693.
12. Ibrahim, H. R.; Kato, A.; Kobayashi, K. Antimicrobial effects of lysozyme against Gram-negative bacteria due to covalent binding of palmitic acid. J. Agric. Food Chem. 1991, 39, 2077-2082.
13. Ibrahim, H. R.; Kobayashi, K.; Kato, A. Length of hydrocarbon chain and antimicrobial action to Gram-negative bacteria of fatty acylated lysozyme. J. Agric. Food Chem. 1993, 41, 1164-1168.
14. Ibrahim, H. R.; Yamada, M.; Kobayashi, K.; Kato, A. Bactericidal action of lysozyme against Gram-negative bacteria due to insertion of a hydrophobic pentapeptide into its C-terminus. Biosci., Biotechnol., Biochem. 1992, 56, 1361-1363.
15. Ibrahim, H. R.; Yamada, M.; Matsushita, K.; Kobayashi, K.; Kato, A. Enhanced bactericidal action of lysozyme to Escherichia coli by inserting a hydrophobic pentapeptide into its C terminus. J. Biol. Chem. 1994, 18, 5059-5063.
16. Arima, H.; Ibrahim, H. R.; Kinoshita, T.; Kato, A. Bactericidal action of lysozymes attached to with various sizes of hydrophobic peptides to the C-terminal using genetic modification. FEBS Lett. 1997, 415, 114-118.
17. Nakamura, S.; Kato, A.; Kobayashi, K. New antimicrobial characteristics of lysozyme-dextran conjugate. J. Agric. Food Chem. 1991, 39, 647-650.
18. Nakamura, S.; Gohya, Y.; Losso, J. N.; Nakai, S.; Kato, A. Protective effect of lysozyme-galactomannan or lysozyme-palmitic acid conjugates against Edwardsiella tarda infection in carp, Cyprinus carpio L. FEBS Lett. 1996, 383, 251-254.
19. Nakamura, S.; Kato, A. Multi-functional biopolymer prepared by covalent attachment of galactomannan to egg-white proteins through naturally occurring Maillard reaction. Nahrung 2000, 44, 201-206.
20. Ibrahim, H. R.; Hatta, H.; Fujiki, M.; Kim, M.; Yamamoto, T. Enhanced antimicrobial action of lysozyme against Gram-negative and Gram-positive bacteria due to modification with perillaldehyde. J. Agric. Food Chem. 1994, 42, 1813-1817.
21. Ibrahim, H. R.; Thomas, U.; Pellegrini, A. A helix-loop peptide at the upper lip of the active site cleft of lysozyme confers potent antimicrobial activity with membrane permeabilization action. J. Biol. Chem. 2001, 276, 43767-43774.
22. Pellegrini, A.; Thomas, U.; Bramaz, N.; Klauser, S.; Hunziker, P.; von Fellenberg, R. Identification and isolation of a bactericidal domain in chicken egg white lysozyme. J. Appl. Microbiol. 1997, 82, 372-378.
23. Pellegrini, A.; Thomas, U.; Wild, P.; Schraner, E.; von Fellenberg, R. Effect of lysozyme or modified lysozyme fragments on DNA and RNA synthesis and membrane permeability of Escherichia coli. Microbiol. Res. 2000, 155, 69-77.
24. Mine, Y.; Ma, F.; Lauriau, S. Antimicrobial peptides released by enzymatic hydrolysis of hen egg white lysozyme. J. Agric. Food Chem. 2004, 52, 1088-1094.
25. During, K.; Porsch, P.; Mahn, A.; Brinkmann, O.; Gieffers, W. The non-enzymatic microbicidal activity of lysozymes. FEBS Lett. 1999, 449, 93-100.
26. Liang, A. H.; Xue, B. Y.; Liang, R. X.; Wang, J. H.; Wang, D. Inhibitory effect of egg white lysozyme on ceftazidime-induced release of endotoxin from Pseudomonas aeruginosa. Yao Xue Xue Bao 2003, 38, 801-804.
27. Sava, G. Pharmacological aspects and therapeutic applications of lysozymes. EXS 1996, 75, 433-449.
28. Tenuovo, J. Clinical applications of antimicrobial host proteins lactoperoxidase, lysozyme and lactoferrin in xerostomia: efficacy and safety. Oral Dis. 2002, 8, 23-29.
29. Lee-Huang, S.; Huang, P. L.; Sun, Y.; Huang, P. L.; Kung, H. F.; Blithe, D. L.; Chen, H. C. Lysozyme and RNases as anti-HIV components in beta-core preparations of human chorionic gonadotropin. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 2678-2681.
30. Pellegrini, A.; Hulsmeier, A. J.; Hunziker, P.; Thomas, U. Proteolytic fragments of ovalbumin display antimicrobial activity. Biochim. Biophys. Acta 2004, 1672, 76-85.
31. Ibrahim, H. R. Ovotransferrin. In Natural Food Antimicrobial Systems; Naidu, A. S., Ed.; CRC Press: New York, 2000; pp 211-226.
32. Abdallah, F. B.; Chahine, J. M. Transferrins, the mechanism of iron release by ovotransferrin. Eur. J. Biochem. 1999, 263, 912-920.
33. Valenti, P.; Antonini, G.; Von Hunolstein, C.; Visca, P.; Orsi, N.; Antonini, E. Studies of the antimicrobial activity of ovotransferrin. Int. J. Tissue React. 1983, 5, 97-105.
34. Baron, F.; Fauvel, S.; Gautier, M. Behaviour of Salmonella enteritidis in industrial egg white: egg naturally contains factors inhibitory to salmonella growth. In Egg Nutrition and Biotechnology; Sim, J. S., Nakai, N., Guenter, W., Eds; CAB International: Oxon, U.K., 2000; pp 417-430.
35. Aguilera, O.; Quiros, L. M.; Fierro, J. F. Transferrins selectively cause ion efflux through bacterial and artificial membranes. FEBS Lett. 2003, 548, 5-10.
36. Ibrahim, H. R.; Sugimoto, Y.; Aoki, T. Ovotransferrin antimicrobial peptide (OTAP-92) kills bacteria through a membrane damage mechanism. Biochim. Biophys. Acta 2000, 1523, 196-205.
37. Giansanti, F.; Rossi, P.; Massucci, M. T.; Botti, D.; Antonini, G.; Valenti, P.; Seganti, L. Antiviral activity of ovotransferrin discloses an evolutionary strategy for the defensive activities of lactoferrin. Biochem. Cell Biol. 2002, 80, 125-130.
38. Green, N. M. Avidin. Adv. Protein Chem. 1975, 29, 85-133.
39. Banks, J. G.; Board, R. G.; Sparks, N. H. C. Natural antimicrobial systems and their potential in food preservation of the future. Biotechnol. Appl. Biochem. 1986, 8, 103-147.
40. Korpela, J.; Salonen, E.-M.; Kuusela, P.; Sarvas, M.; Vaheri, A. Binding of avidin to bacteria and to the outer membrane porin of Escherichia coli. FEMS Microbiol. Lett. 1984, 22, 3-10.
41. Ibrahim, H. R. Insights into the structure-function relationships of ovalbumin, ovotransferrin, and lysozyme. In Hen Eggs, Their Basic and Applied Science; Yamamoto, T., Juneja, L. R., Hatta, H., Kim, M., Eds.; CRC Press: New York, 1997; pp 37-56.
42. Tsuge, Y.; Shimoyamada, M.; Watanabe, K. Binding of egg white proteins to viruses. Biosci., Biotechnol., Biochem. 1996, 60, 1503-1504.
43. Tsuge, Y.; Shimoyamada, M.; Watanabe, K. Differences in hemagglutination inhibition activity against bovine rotavirus and hen newcastle disease virus based on the subunits in hen egg white ovomucin. Biosci., Biotechnol., Biochem. 1996, 60, 1505-1506.
44. Tsuge, Y.; Shimoyamada, M.; Watanabe, K. Structural features of newcastle disease virus-and anti-ovomucin antibody-binding glycopeptides from Pronase-treated ovomucin. J. Agric. Food Chem. 1997, 45, 2393-2398.
45. Tsuge, Y.; Shimoyamada, M.; Watanabe, K. Binding of ovomucin to Newcastle disease virus and anti-ovomucin antibodies and its heat stability based on binding abilities. J. Agric. Food Chem. 1997, 45, 4629-4634.
46. Watanabe, K.; Tsuge, Y.; Shimoyamada, M. Binding activities of Pronase-treated fragments from egg white ovomucin with anti-ovomucin antibodies and Newcastle disease virus. J. Agric. Food Chem. 1998, 46, 4501-4506.
47. Sharon, N.; Ofek, I. Fighting infectious diseases with inhibitors of microbial adhesion to host tissues. Crit. Rev. Food Sci. Nutr. 2002, 42, 267-272.
48. Kobayashi, K.; Hattori, M.; Hara-Kudo, Y.; Okubo, T.; Yamamoto, S.; Takita, T.; Sugita-Konishi, Y. Glycopeptide derived from hen egg ovomucin has the ability to bind enterohemorrhagic Escherichia coli O157:H7. J. Agric. Food Chem. 2004, 52, 5740-5746.
49. Wahn, V. Primary immunodeficiencies caused by defects of cytokines and cytokine receptors. In Methods in Molecular Biology: Cytokines and Colony Stimulating Factors: Methods and Protocols; Korholz, D., Kiess, W., Eds.; Humana Press: Totowa, NJ, 2003; Vol. 215, pp 3-12.
50. Mire-Sluis, A. R. Analytical characterization of cytokines and growth factors. In Biological Characterization and Assay of Cytokines and Growth Factors; Brown, F., Mire-Sluis, A. R., Eds.; Karger: Basel, Switzerland, 1999; Vol. 97, pp 3-9.
51. Fan, X.; Subramaniam, R.; Weiss, M. F.; Monnier, V. M. Methylglyoxal-bovine serum albumin stimulates tumor necrosis factor alpha secretion in RAW 264.7 cells through activation of mitogen-activating protein kinase, nuclear factor kappaB and intracellular reactive oxygen species formation. Arch. Biochem. Biophys. 2003, 409, 274-286.
52. Vidovic, D.; Graddis, T.; Chen, F.; Slagle, P.; Diegel, M.; Stepan, L.; Laus, R. Antitumor vaccination with HER-2-derived recombinant antigens. Int. J. Cancer 2002, 102, 660-664.
53. Goldberg, J.; Shrikant, P.; Mescher, M. F. In vivo augmentation of tumor-specific CTL responses by class I/peptide antigen complexes on microspheres (large multivalent immunogen). J. Immunol. 2003, 170, 228-235.
54. He, X.; Tsang, T. C.; Luo, P.; Zhang, T.; Harris, D. T. Enhanced tumor immunogenicity through coupling cytokine expression with antigen presentation. Cancer Gene Ther. 2003, 10, 669-677.
55. Tezuka, H.; Yoshikawa, M. Presented at the Annual Meeting of the Japan Society for Bioscience, Biotechnology, and Agrochemistry, Tokyo, Japan, 1995; p 163.
56. Tanizaki, H.; Tanaka, H.; Iwata, H.; Kato, A. Activation of macrophages by sulfated glycopeptides in ovomucin, yolk membrane, and chalazae in chicken eggs. Biosci., Biotechnol., Biochem. 1997, 61, 1883-1889.
57. Holen, E.; Bolann, B.; Elsayed, S. Novel B and T cell epitopes of chicken ovomucoid (Gal d 1) induce T cell secretion of IL-6, IL-13, and IFN-gamma. Clin. Exp. Allergy 2001, 31, 952-964.
58. Asakura, K.; Kojima, T.; Shirasaki, H.; Kataura, A. Evaluation of the effects of antigen specific immunotherapy on chronic sinusitis in children with allergy. Auris Nasus Larynx 1990, 17, 33-38.
59. Sugahara, T.; Murakami, F.; Yamada, Y.; Sasaki, T. The mode of actions of lysozyme as an immunoglobulin production stimulating factor. Biochim. Biophys. Acta 2000, 1475, 27-34.
60. Xie, H.; Huff, G. R.; Huff, W. E.; Balog, J. M.; Rath, N. C. Effects of ovotransferrin on chicken macrophages and heterophil-granulocytes. Dev. Comp. Immunol. 2002, 26, 805-815.
61. Otani, H.; Odashima, M. Inhibition of proliferative responses of mouse spleen lymphocytes by lacto- and ovotransferrins. Food Agric. Immunol. 1997, 9, 193-202.
62. Hirota, Y.; Yang, M. P.; Araki, S.; Yoshihara, K.; Furusawa, S.; Yasuda, M.; Mohamed, A.; Matsumoto, Y.; Onodera, T. Enhancing effects of chicken egg white derivatives on the phagocytic response in the dog. J. Vet. Med. Sci. 1995, 57, 825-829.
63. Kato, T.; Imatani, T.; Miura, T.; Minaguchi, K.; Saitoh, E.; Okuda, K. Cytokine-inducing activity of family 2 cystatins. Biol. Chem. 2000, 381, 1143-1147.
64. Verdot, L.; Lalmanach, G.; Vercruysse, V.; Hartmann, S.; Lucius, R.; Hoebeke, J.; Gauthier, F.; Vray, B. Cystatins up-regulate nitric oxide release from interferon-gamma-activated mouse peritoneal macrophages. J. Biol. Chem. 1996, 271, 28077-28081.
65. Verdot, L.; Lalmanach, G.; Vercruysse, V.; Hoebeke, J.; Gauthier, F.; Vray, B. Chicken cystatin stimulates nitric oxide release from interferon-gamma-activated mouse peritoneal macrophages via cytokine synthesis. Eur. J. Biochem. 1999, 266, 1111-1117.
66. Sava, G. Reduction of B16 melanoma metastases by oral administration of egg-white lysozyme. Cancer Chemother. Pharmacol. 1989, 25, 221-222.
67. Sava, G.; Benetti, A.; Ceschia, V.; Pacor, S. Lysozyme and cancer: role of exogenous lysozyme as anticancer agent (review). Anticancer Res. 1989, 9, 583-591.
68. Sava, G.; Ceschia, V.; Pacor, S.; Zabucchi, G. Observations on the antimetastatic action of lysozyme in mice bearing Lewis lung carcinoma. Anticancer Res. 1991, 11, 1109-1113.
69. Das, S.; Banerjee, S.; Gupta, J. D. Experimental evaluation of preventative and therapeutic potential of lysozyme. Chemotherapy 1992, 38, 350-357.
70. Pacor, S.; Giacomello, E.; Bergamo, A.; Clerici, K.; Zacchigna, M.; Boccu, E.; Sava, G. Antimetastatic action and lymphocyte activation by the modified lysozyme mPEG-Lyso in mice with MCa mammary carcinoma. Anticancer Res. 1996, 16, 2559-2564.
71. Pacor, S.; Gagliardi, R.; Di Daniel, E.; Vadori, M.; Sava, G. In vitro down regulation of ICAM-1 and E-cadherin and in vitro reduction of lung metastases of TS/A adenocarcinoma by a lysozyme derivative. Int. J. Mol. Med. 1999, 4, 369-375.
72. Sava, G.; Pacor, S.; Dasic, G.; Bergamo, A. Lysozyme stimulates lymphocyte response to ConA and IL-2 and potentiates 5-fluorouracil action on advanced carcinomas. Anticancer Res. 1995, 15, 1883-1888.
73. Shcherbakova, E. G.; Bukhman, V. M.; Isakova, E. B.; Bodiagin, D. A.; Arkhipova, N. A.; Rastunova, G. A.; Vorob'eva, L. S.; Lipatov, N. N. Effect of lysozyme on the growth of murine lymphoma and antineoplastic activity of cyclophosphamide. Antibiotic. Khimioter. 2002, 47, 3-8.
74. Watanabe, K.; Tsuge, Y.; Shimoyamada, M.; Ogama, N.; Ebina, T. Antitumor effects of Pronase-treated fragments, glycopeptides, from ovomucin in hen egg white in a double grafted tumor system. J. Agric. Food Chem. 1998, 46, 3033-3038.
75. Oguro, T.; Ohaki, Y.; Asano, G.; Ebina, T.; Watanabe, K. Ultrastructural and immunohistochemical characterization on the effect of ovomucin in tumor angiogenesis. Jpn. J. Clin. Electron Microsc. 2001, 33, 89-99.
76. Davalos, A.; Miguel, M.; Bartolome, B.; Lopez-Fandino, R. Antioxidant activity of peptides derived from egg white proteins by enzymatic hydrolysis. J. Food Prot. 2004, 67, 1939-1944.
77. Fujita, H.; Usui, H.; Kurahashi, K.; Yoshikawa, M. Isolation and characterization of ovokinin, a bradykinin B1 agonist peptide derived from ovalbumin. Peptides 1995, 16, 785-790.
78. Matoba, N.; Usui, H.; Fujita, H.; Yoshikawa, M. A novel antihypertensive peptide derived from ovalbumin induces nitric oxide-mediated vasorelaxation in an isolated SHR mesenteric artery. FEBS Lett. 1999, 452, 181-184.
79. Fujita, H.; Sasaki, R.; Yoshikawa, M. Potentiation of the antihypertensive activity of orally administered ovokinin, a vasorelaxing peptide derived from ovalbumin, by emulsification in egg phosphatidylcholine. Biosci., Biotechnol., Biochem. 1995, 59, 2344-2345.
80. Matoba, N.; Yamada, Y.; Usui, H.; Nakagiri, R.; Yoshikawa, M. Designing potent derivatives of ovokinin(2-7), an antihypertensive peptide derived from ovalbumin. Biosci., Biotechnol., Biochem. 2001, 65, 736-739.
81. Yamada, Y.; Matoba, N.; Usui, H.; Onishi, K.; Yoshikawa, M. Design of a highly potent anti-hypertensive peptide based on ovokinin(2-7). Biosci., Biotechnol., Biochem. 2002, 66, 1213-1217.
82. Yoshikawa, M.; Fujita, H. Studies on the optimum conditions to utilize biologically active peptides derived from food proteins. In Developments in Food Engineering; Yano, T., Matsuno, R., Nakamura, K., Eds.; Blackie Academic and Professional: New York, 1994; pp 1053-1055.
83. Miguel, M.; Recio, I.; Gomez-Ruiz, J. A.; Ramos, M.; Lopez-Fandino, R. Angiotensin I-converting enzyme inhibitory activity of peptides derived from egg white proteins by enzymatic hydrolysis. J. Food Prot. 2004, 67, 1914-1920.
84. Ames, B. N.; Shigenaga, M. K.; Hagen, T. M. Oxidants, antioxidants, and the degenerative diseases of aging. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 7915-7922.
85. Abrahamson, M.; Alvarez-Fernandez, M.; Nathanson, C. M. Cystatins. Biochem. Soc. Symp. 2003, 70, 179-199.
86. Henskens, Y. M. C.; Veerma, E. C. I.; Nieuw Amerongen, A. V. Cystatins in health and disease. Biol. Chem. 1996, 377, 71-86.
87. Bjorck, L. Proteinase inhibition, immunoglobulin-binding proteins and a novel antimicrobial principle. Mol. Microbiol. 1990, 4, 1439-1442.
88. Nakai, S. Molecular modifications of egg proteins for functional improvement. In Egg Nutrition and Biotechnology; Sim, J. S., Nakai, S., Guenter, W., Eds.; CAB International: Oxon, U.K., 2000; pp 205-217.
89. Blankenvoorde, M. F.; Henskens, Y. M.; van't Hof, W.; Veerman, E.; Nieuw Amerongen, A. V. Inhibition of the growth and cysteine proteinase activity of Porphyromonas gingivalis by human salivary cystatin S and chicken cystatin. Biol. Chem. 1996, 377, 847-850.
90. Blankenvoorde, M. F.; van't Hof, W.; Walgreen-Weterings, E.; van Steenbergen, T. J.; Brand, H. S.; Veerman, E. C.; Nieuw Amerongen, A. V. Cystatin and cystatin-derived peptides have antibacterial activity against the pathogen Porphyromonas gingivalis. Biol. Chem. 1998, 379, 1371-1375.
91. Kitamoto, T.; Nakashima, M.; Ikai, A. Hen egg white ovomacroglobulin has a protease inhibitory activity. J. Biochem. 1982, 92, 1679-1682.
92. Molla, A.; Matsumura, Y.; Yamamoto, T.; Okamura, R.; Maeda, H. Pathogenic capacity of proteases from Serratia marcescens and Pseudomonas aeruginosa and their suppression by chicken egg white ovomacroglobulin. Infect. Immun. 1987, 55, 2509-2517.
93. Miyagawa, S.; Matsumoto, K.; Kamata, R.; Okamura, R.; Maeda, H. Spreading of Serratia marcescens in experimental keratitis and growth suppression by chicken egg white ovomacroglobulin. Jpn. J. Ophthalmol. 1991, 35, 402-410.
94. Miyagawa, S.; Nishino, N.; Kamata, R.; Okamura, R.; Maeda, H. Effects of protease inhibitors on growth of Serratia marcescens and Pseudomonas aeruginosa. Microb. Pathog. 1991, 11, 137-141.
95. Miyagawa, S.; Kamata, R.; Matsumoto, K.; Okamura, R.; Maeda, H. Therapeutic intervention with chicken egg white ovomacroglobulin and a new quinolone on experimental Pseudomonas keratitis. Graefes Arch. Clin. Exp. Ophthalmol. 1994, 232, 488-493.
96. Miyagawa, S.; Kamata, R.; Matsumoto, K.; Okamura, R.; Maeda, H. Inhibitory effects of ovomacroglobulin on bacterial keratitis in rabbits. Graefes Arch. Clin. Exp. Ophthalmol. 1991, 229, 281-286.
97. Ijiri, Y.; Yamamoto, T.; Kamata, R.; Aoki, H.; Matsumoto, K.; Okamura, R.; Kambara, T. The role of Pseudomonas aeruginosa elastase in corneal ring abscess formation in pseudomonal keratitis. Graefes Arch. Clin. Exp. Ophthalmol. 1993, 231, 521-528.
98. Maeda, H.; Akaike, T.; Sakata, Y.; Maruo, K. Role of bradykinin in microbial infection: enhancement of septicemia by microbial proteases and kinin. Agents Actions Suppl. 1993, 42, 159-165.
99. Maruo, K.; Akaike, T.; Ono, T.; Maeda, H. Involvement of bradykinin generation in intravascular dissemination of Vibrio vulnificus and prevention of invasion by a bradykinin antagonist. Infect. Immun. 1998, 66, 866-869.
100. Tomimatsu, Y.; Clary, J. J.; Bartulovich, J. J. Physical characterization of ovoinhibitor, a trypsin and chymotrypsin inhibitor from chicken egg white. Arch. Biochem. Biophys. 1966, 115, 536-544.
101. Ebina, T.; Tsukada, K. Protease inhibitors prevent the development of human rotavirus-induced diarrhea in suckling mice. Microbiol. Immunol. 1991, 35, 583-588.
102. Korant, B. D.; Brzin, J.; Turk, V. Cystatin, a protein inhibitor of cysteine proteinases alters viral protein cleavages in infected human cells. Biochem. Biophys. Res. Commun. 1985, 127, 1072-1076.
103. Korant, B. D.; Towatari, T.; Ivanoff, L.; Petteway, S., Jr.; Brzin, J.; Lenarcic, B.; Turk, V. Viral therapy: prospects for protease inhibitors. J. Cell Biochem. 1986, 32, 91-95.
104. Das, L.; Datta, N.; Bandyopadhyay, S.; Das, P. K. Successful therapy of lethal murine visceral leishmaniasis with cystatin involves up-regulation of nitric oxide and a favourable T cell response. J. Immunol. 2001, 166, 4020-4028.
105. Kennedy, A. R. Anticarcinogenic activity of protease inhibitors. In Protease Inhibitors as Cancer Chemopreventative Agents; Troll, W., Kennedy, A. R., Eds.; Plenum Press: New York, 1993; pp 9-64.
106. Konduri, S. D.; Yanamandra, N.; Siddique, K.; Joseph, A.; Dinh, D. H.; Olivero, W. C.; Gujrati, M.; Kouraklis, G.; Swaroop, A.; Kyritsis, A. P.; Rao, J. S. Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene 2002, 21, 8705-8712.
107. Nagai, A.; Terashima, M.; Harada, T.; Shimode, K.; Takeuchi, H.; Murakawa, Y.; Nagasaki, M.; Nakano, A.; Kobayashi, S. Cathepsin B and H activities and cystatin C concentrations in cerebrospinal fluid from patients with leptomeningeal metastasis. Clin. Chim. Acta 2003, 329, 53-60.
108. Cegnar, M.; Premzl, A.; Zavasnik-Bergant, V.; Kristl, J.; Kos, J. Poly(lactide-co-glycolide) nanoparticles as a carrier system for delivering cysteine protease inhibitor cystatin into tumor cells. Exp. Cell Res. 2004, 301, 223-231.
109. Premzl, A.; Puizdar, V.; Zavasnik-Bergant, V.; Kopitar-Jerala, N.; Lah, T. T.; Katunuma, N.; Sloane, B. F.; Turk, V.; Kos, J. Invasion of ras-transformed breast epithelial cells depends on the proteolytic activity of cysteine and aspartic proteinases. Biol. Chem. 2001, 382, 853-857.
110. Saleh, Y.; Siewinski, M.; Kielan, W.; Ziolkowski, P.; Grybos, M.; Rybka, J. Regulation of cathepsin B and L expression in vitro in gastric cancer tissues by egg cystatin. J. Exp. Ther. Oncol. 2003, 3, 319-324.
111. Muehlenweg, B.; Assfalg-Machleidt, I.; Parrado, S. G.; Burgle, M.; Creutzburg, S.; Schmitt, M.; Auerswald, E. A.; Machleidt, W.; Magdolen, V. A novel type of bifunctional inhibitor directed against proteolytic activity and receptor/ligand interaction. Cystatin with a urokinase receptor binding site. J. Biol. Chem. 2000, 275, 33562-33566.
112. Krol, J.; Kopitz, C.; Kirschenhofer, A.; Schmitt, M.; Magdolen, U.; Kruger, A.; Magdolen, V. Inhibition of intraperitoneal tumor growth of human ovarian cancer cells by bi- and trifunctional inhibitors of tumor-associated proteolytic systems. Biol. Chem. 2003, 384, 1097-1102.
113. Krol, J.; Sato, S.; Rettenberger, P.; Assfalg-Machleidt, I.; Schmitt, M.; Magdolen, V.; Magdolen, U. Novel bi- and trifunctional inhibitors of tumor-associated proteolytic systems. Biol. Chem. 2003, 384, 1085-1096.
114. Wu, J.; Akaike, T.; Hayashida, K.; Okamoto, T.; Okuyama, A.; Maeda, H. Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases. Jpn J. Cancer Res. 2001, 92, 439-451.
115. Kato, I.; Schrode, J.; Kohr, W. J.; Laskowski, M., Jr. Chicken ovomucoid: determination of its amino acid sequence, determination of the trypsin reactive site, and preparation of all three domains. Biochemistry 1987, 26, 193-201.
116. Shah, R. B.; Khan, M. A. Protection of salmon calcitonin breakdown with serine proteases by various ovomucoid species for oral drug delivery. J. Pharm. Sci. 2004, 93, 392-406.
117. Agarwal, V.; Reddy, I. K.; Khan, M. A. Oral delivery of proteins: effect of chicken and duck ovomucoid on the stability of insulin in the presence of α-chymotrypsin and trypsin. Pharm. Pharmacol. Commun. 2000, 6, 223-227.
118. Agarwal, V.; Nazzal, S.; Reddy, I. K.; Khan, M. A. Transport studies of insulin across rat jejunum in the presence of chicken and duck ovomucoids. J. Pharm. Pharmacol. 2001, 53, 1131-1138.
119. Agarwal, V.; Reddy, I. K.; Khan, M. A. Polymethylacrylate based microparticulates of insulin for oral delivery: preparation and in vitro dissolution stability in the presence of enzyme inhibitors. Int. J. Pharm. 2001, 225, 31-39.
120. Hilpert, K.; Wessner, H.; Schneider-Mergener, J.; Welfle, K.; Misselwitz, R.; Welfle, H.; Hocke, A. C.; Hippenstiel, S.; Hohne, W. Design and characterization of a hybrid miniprotein that specifically inhibits porcine pancreatic elastase. J. Biol. Chem. 2003, 278, 24986-24993.
121. Brand, H. S.; Lerner, U. H.; Grubb, A.; Beertsen, W.; Nieuw Amerongen, A. V.; Everts, V. Family 2 cystatins inhibit osteoclast-mediated bone resorption in calvarial bone explants. Bone 2004, 35, 689-696.
122. Maliar, T.; Balaz, S.; Tandlich, R.; Sturdik, E. Viral proteinases-possible targets of antiviral drugs. Acta Virol. 2002, 46, 131-140.
123. Paoletti, F.; Mocali, A.; Tombaccini, D. Cysteine proteases are responsible for characterisitic transketolase alterations in Alzheimer fibroblasts. J. Cell Physiol. 1997, 172, 63-68.
124. Schimmoller, F.; Higaki, J. N.; Cordell, B. Amyloid forming proteases: therapeutic targets for Alzheimer's disease. Curr. Pharm. Des. 2002, 8, 2521-2531.
125. Hytonen, V. P.; Laitinen, O. H.; Grapputo, A.; Kettunen, A.; Savolainen, J.; Kalkkinen, N.; Martilla, A. T.; Norlund, H. R.; Nyholm, T. K. M.; Paganelli, G.; Kulomaa, M. K. Characterisation of poultry egg-white avidins and their potential as tools in pretargeting cancer treatment. Biochem. J. 2003, 372, 219-225.
126. Moro, M.; Pelagi, M.; Fulci, G.; Paganelli, G.; Dellabona, P.; Casorati, G.; Siccardi, A. G.; Corti, A. Tumor cell pretargeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha. Cancer Res. 1997, 57, 1922-1928.
127. Corti, A.; Gaspard, A.; Sacchi, A.; Curnis, F.; Sangregorio, R.; Columbo, B.; Siccardi, A. G.; Magni, F. Tumor targeting with biotinylated tumor necrosis factor alpha: structure-activity relationships and mechanism of action on avidin pretargeted tumor cells. Cancer Res. 1998, 58, 3866-3872.
128. Gasparri, A.; Moro, M.; Curnis, F.; Sacchi, A.; Pagano, S.; Veglia, F.; Casorati, G.; Siccardi, A. G.; Dellabona, P.; Corti, A. Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models. Cancer Res. 1999, 59, 2917-2923.
129. Yao, Z.; Zhang, M.; Sakahara, H.; Saga, T.; Arano, Y.; Konishi, J. Avidin targeting of intraperitoneal tumor xenografts. J. Natl. Cancer Inst. 1998, 90, 25-29.
130. Bickel, U.; Yoshikawa, T.; Pardridge, W. M. Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Deliv. Rev. 2001, 46, 247-279.
131. Plate, N. A.; Valuev, I. L.; Sytov, G. A.; Valuev, L. I. Mucoadhesive polymers with immobilized proteinase inhibitors for oral administration of protein drugs. Biomaterials 2002, 23, 1673-1677.
132. Burley, R. W.; Cook, W. H. Isolation and composition of avian egg yolk granules and their constituents α- and β-lipovitellines. Can. J. Biochem. Physiol. 1961, 39, 1295-1307.
133. Sim, J. S.; Sunwoo, H. H.; Lee, E. N. Ovoglobulin IgY. In Natural Food Antimicrobial Systems; Naidu, A. A., Ed.; CRC Press: New York, 2000; pp 227-252.
134. Kovacs-Nolan, J.; Mine, Y. Avian egg antibodies: basic and potential applications. Avian Poult. Biol. Rev. 2004, 15, 25-46.
135. Kovacs-Nolan, J.; Mine, Y. Passive immunization through avian egg antibodies. Food Biotechnol. 2004, 18, 39-62.
136. Carlander, D.; Kollberg, H.; Wejaker, P.-E.; Larsson, A. Peroral immunotherapy with yolk antibodies for the prevention and treatment of enteric infections. Immunol. Res. 2000, 21, 1-6.
137. Carlander, D.; Stalberg, J.; Larsson, A. Chicken antibodies: a clinical chemistry perspective. Upsala J. Med. Sci. 1999, 104, 179-190.
138. Karlsson, M.; Kollberg, H.; Larsson, A. Chicken IgY: utilizing the evolutionary advantage. World's Poult. Sci. J. 2004, 60, 341-347.
139. Otake, S.; Nishihara, Y.; Makimura, M.; Hatta, H.; Kim, M.; Yamamoto, T.; Hirasawa, M. Protection of rats against dental caries by passive immunization with hen egg yolk antibody (IgY). J. Dent. Res. 1991, 70, 162-166.
140. Hatta, H.; Tsuda, K.; Ozeki, M.; Kim, M.; Yamamoto, T.; Otake, S.; Hirosawa, M.; Katz, J.; Childers, N. K.; Michalek, S. M. Passive immunization against dental plaque formation in humans: effect of a mouth rinse containing egg yolk antibodies (IgY) specific to Streptococcus mutans. Caries Res. 1997, 31, 268-274.
141. Chang, H. M.; Ou-Yang, R. F.; Chen, Y. T.; Chen, C. C. Productivity and some properties of immunoglobulin specific against Streptococcus mutans serotype c in chicken egg yolk (IgY). J. Agric. Food Chem. 1999, 47, 61-66.
142. Smith, D. J.; King, W. F.; Godiska, R. Passive transfer of immunoglobulin Y to Streptococcus mutans glucan binding protein B can confer protection against experimental dental caries. Infect. Immun. 2001, 69, 3135-3142.
143. Kruger, C.; Pearson, S. K.; Kodama, Y.; Vacca Smith, A.; Bowen, W. H.; Hammarstrom, L. The effects of egg-derived antibodies to glucotransferases on dental caries in rats. Caries Res. 2004, 38, 9-14.
144. Carlander, D.; Kollberg, H.; Wejaker, P.-E.; Larsson, A. Prevention of chronic Pseudomonas aeruginosa colonization by gargling with specific antibodies: a preliminary report. In Egg Nutrition and Biotechnology; Sim, J. S., Nakai, S., Guenter, W., Eds.; CABI Publishing: New York, 2000; pp 371-374.
145. Kollberg, H.; Carlander, D.; Olesen, H.; Wejaker, P.-E.; Johannesson, M.; Larsson, A. Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study. Pediatr. Pulmonol. 2003, 35, 433-440.
146. Horie, K.; Horie, N.; Abdou, A. M.; Yang, J.-O.; Yun, S.-S.; Chun, C.-K.; Kim, M.; Hatta, H. Suppressive effect of functional drinking yogurt containing specific egg yolk immunoglobulin on Helicobacter pylori in humans. J. Dairy Sci. 2004, 87, 4703-4079.
147. Brady, D.; Gaines, S.; Fenelon, L.; McPartlin, J.; O'Farrelly, C. A lipoprotein-derived antimicrobial factor from hen-egg yolk is active against Streptococcus species. J. Food Sci. 2002, 67, 3096-3103.
148. Sattar Khan, M. A.; Nakamura, S.; Ogawa, M.; Akita, E.; Azakami, H.; Kato, A. Bactericidal action of egg yolk phosvitin against Escherichia coli under thermal stress. J. Agric. Food Chem. 2000, 48, 1503-1506.
149. Choi, I.; Jung, C.; Seog, H.; Choi, H. Purification of phosvitin from egg yolk and determination of its physiochemical properties. Food Sci. Biotechnol. 2004, 13, 434-437.
150. Deignan, T.; Alwan, A.; Malone, L.; Kelly, J.; O'Farrelly, C. Hen egg yolk prevents bacterial adherence: a novel function for a familiar food. J. Food Sci. 2001, 66, 158-161.
151. Sugita-Konishi, Y.; Kobayashi, K.; Sakanaka, S.; Juneja, L. R.; Amano, F. Preventive effect of sialylglycopeptide-nondigestive polysaccharide conjugates on Salmonella infection. J. Agric. Food Chem. 2004, 52, 5443-5448.
152. Koketsu, M.; Nitoda, T.; Juneja, L. R.; Kim, M.; Kashimura, N.; Yamamoto, T. Sialyloligosaccharides from egg yolk as an inhibitor of rotaviral infection. J. Agric. Food Chem. 1995, 43, 858-861.
153. Koketsu, M.; Enoki, Y.; Juneja, L. R.; Kim, M.; Yamamoto, T. Isolation of Sialyloligosaccharides from egg yolk using enzymes and some biofunctional activities of the oligosaccharides isolated. J. Appl. Glycosci. 1996, 43, 283-287.
154. Sugita-Konishi, Y.; Sakanaka, S.; Sasaki, K.; Juneja, L. R.; Noda, T.; Amano, F. Inhibition of bacterial adhesion and Salmonella infection in BALB/c mice by sialyloligosaccharides and their derivatives from chicken egg yolk. J. Agric. Food Chem. 2002, 50, 3607-3613.
155. Kassaify, Z. G.; Mine, Y. Effect of food protein supplements on Salmonella enteritidis infection and prevention in laying hens. Poult. Sci. 2004, 83, 753-760.
156. Kassaify, Z. G.; Mine, Y. Nonimmunized egg yolk powder can suppress the colonization of Salmonella typhimurium, Escherichia coli O157:H7, and Campylobacter jejuni in laying hens. Poult. Sci. 2004, 83, 1497-1506.
157. Gaines, S.; James, T. C.; Folan, M.; Baird, A. W.; O'Farrelly, C. A novel spectrofluorometric assay for Streptococcs mutans adherence to hydroxylapatite. J. Microbiol. Methods 2003, 54, 315-323.
158. Yamamoto, Y.; Sogo, N.; Iwao, R.; Miyamoto, T. Antioxidant effect of egg yolk on linoleate in emulsions. Agric. Biol. Chem. 1990, 54, 3099-3104.
159. Yamamoto, Y.; Omori, M.; Miyamoto, T. Antioxidant effects of egg yolk on linoleic acid and lard. Agric. Biol. Chem. 1991, 55, 2403-2404.
160. Sugino, H.; Ishikawa, M.; Nitoda, T.; Koketsu, M.; Juneja, L. R.; Kim, M.; Yamamoto, T. Antioxidative activity of egg yolk phospholipids. J. Agric. Food Chem. 1997, 45, 551-554.
161. Lu, C. L.; Baker, R. Characteristics of egg yolk phosvitin as an antioxidant for inhibiting metal-catalyzed phospholipid oxidations. Poult. Sci. 1986, 65, 2065-2070.
162. Nakamura, S.; Ogawa, M.; Nakai, S.; Kato, A.; Kitts, D. D. Antioxidant activity of a Maillard-type phosvitin-galactomannan conjugate with emulsifying properties and heat stability. J. Agric. Food. Chem. 1998, 46, 3958-3963.
163. Ishikawa, S.; Yano, Y.; Arihara, K.; Itoh, M. Egg yolk phosvitin inhibits hydroxyl radical formation from the Fenton reaction. Biosci., Biotechnol., Biochem. 2004, 68, 1324-1331.
164. Jiang, B.; Mine, Y. Preparation of novel functional oligophosphopeptides from hen egg yolk phosvitin. J. Agric. Food Chem. 2000, 48, 990-994.
165. Jiang, B.; Mine, Y. Phosphopeptides derived from hen egg yolk phosvitin: effect of molecular size on the calcium-binding properties. Biosci., Biotechnol., Biochem. 2001, 65, 1187-1190.
166. Juneja, L. R. Egg yolk lipids. In Hen Eggs, Their Basic and Applied Science; Yamamoto, T., Juneja, L. R., Hatta, H., Kim, M., Eds.; CRC Press: New York, 1997; pp 73-98.
167. Makrides, M.; Hawkes, J. S.; Neumann, M. A.; Gibson, R. A. Nutritional effect of including egg yolk in the weaning diet of breast-fed and formula-fed infants: a randomized controlled trial. Am. J. Clin. Nutr. 2002, 75, 1084-1092.
168. Rabinowich, H.; Lyte, M.; Steiner, Z.; Klajman, A.; Shinitzky, M. Augmentation of mitogen responsiveness in the aged by a special lipid diet AL 721. Mech. Ageing Dev. 1987, 40, 131-138.
169. Carlson, S. E.; Montalto, M. B.; Ponder, D. L.; Werkman, S. H.; Korones, S. B. Lower incidence of necrotizing enterocolitis in infants fed a preterm formula with egg phospholipids. Pediatr. Res. 1998, 44, 491-498.
170. Murata, M.; Imaizumi, K.; Sugano, M. Effect of dietary phospholipids and their constituent bases on serum lipids and apolipoproteins in rats. J. Nutr. 1982, 112, 1805-1808.
171. Jiang, Y.; Noh, S. K.; Koo, S. I. Egg phosphatidylcholine decreases the lymphatic absorption of cholesterol in rats. J. Nutr. 2001, 131, 2358-2363.
172. Masuda, Y.; Kokubu, T.; Yamashita, M.; Ikeda, H.; Inoue, S. Egg phosphatidylcholine combined with vitamin B12 improved memory impairment following lesioning of nucleus basalis in rats. Life Sci. 1998, 62, 813-822.
173. Favreliere, S.; Perault, M. C.; Huguet, F.; De Javel, D.; Bertrand, N.; Piriou, A.; Durand, G. DHA-enriched phospholipid diets modulate age-related alterations in rat hippocampus. Neurobiol. Ageing 2003, 24, 233-243.
174. Gutierrez, M. A.; Takahashi, H.; Juneja, L. R. Nutritive evaluation of hen eggs. In Hen Eggs, Their Basic and Applied Science; Yamamoto, T., Juneja, L. R., Hatta, H., Kim, M., Eds.; CRC Press: New York, 1997; pp 25-35.
175. Lim, S. Y.; Suzuki, H. Intakes of dietary docosahexaenoic acid ethyl ester and egg phosphatidylcholine improve maze-learning ability in young and old mice. J. Nutr. 2000, 130, 1629-1632.
176. Simopoulos, A. P. Essential fatty acids in health and chronic disease. Am. J. Clin. Nutr. 1999, 70 (Suppl. 3), 560S-569S.
177. Simopoulos, A. P. Omega-3 fatty acids in inflammation and autoimmune diseases. J. Am. Coll. Nutr. 2002, 21, 495-505.
178. Sheppard, E. H. Specialty eggs: n-3 fatty acid-enriched eggs. In Eggs and Health Promotion Eggs and Health Promotion; Watson, R. R., Ed.; Iowa State Press: Ames, IA, 2002; pp 37-44.
179. Bourre, J. M. Roles of unsaturated fatty acids (especially omega-3 fatty acids) in the brain at various ages and during ageing. J. Nutr. Health Aging 2004, 8, 163-174.
180. Sim, J. S.; Sunwoo, H. H. Designer eggs: nutritional and functional significance. In Eggs and Health Promotion; Watson, R. R., Ed.; Iowa State Press: Ames, IA, 2002; pp 19-35.
181. Lewis, N. M.; Seburg, S.; Flanagan, N. L. Enriched eggs as a source of n-3 polyunsaturated fatty acids for humans. Poult. Sci. 2000, 79, 971-974.